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studies of this species. Our main con-
cern about their work is the inaccurate
picture that is presented of the cholera
epidemic in Brazil. Some of the state-
ments made in the final paragraphs
are in disagreement with the official
epidemiologic records and the charac-
teristics of the Vibrio  bacteria that
occurred in Brazil during the 1990s
epidemic (2).
In 1991, the seventh cholera pan-
demic reached South America by the
Pacific coast, spreading to Brazil in
the same year (3). In Brazil, the first
cholera cases were reported in the
Amazon region bordering Peru; with-
in a few months a large number of
cholera cases were recorded in states
facing the Atlantic Ocean in the north-
eastern region (2). According to the
official figures of the Brazilian
Ministry of Health (2), 168,598 cases
of cholera caused by a V. cholerae O1
El Tor strain occurred in Brazil from
1991 to 2001. Of these, 155,363
(92.1%) occurred in the northeastern
area of the country, with 2,037 deaths.
From 2001 to 2003, the number of
confirmed cases was 4,756, 734, and
7, respectively.
Sarkar et al. (1) indicate that
60,000 cases occurred from 1991 to
2001 in Rio de Janeiro, a city local-
ized in the southeastern region; the
official records report only 349 cases.
The statement that “since 1993, no
cholera cases caused by O1 have been
reported” is also perplexing. From
1994 to 2001, the official records
report 68,583 cases of cholera in
Brazil (51,324 of these in 1994, the
second major year of cholera inci-
dence). Are the authors suggesting
that this number of cases was caused
by non-O1 V. cholerae? The official
records state that the cholera epidem-
ic in Brazil was caused by an El Tor
O1 strain (4,5). 
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Fluoroquinolone-
resistant
Salmonella
Paratyphi A 
To the Editor: Fluoroquinolones
have been the drug of choice for treat-
ing typhoid and paratyphoid fever
since the beginning of the 1990s.
Multidrug-resistant strains began to
prevail in disease-endemic areas, and
former first-line antimicrobial drugs,
such as chloramphenicol, were some-
times ineffective (1). In recent years,
however, strains with decreased sus-
ceptibility to quinolones have
emerged, and clinical treatment fail-
ure is a serious concern (2–5).
An 87-year-old woman was
referred from a local clinic to
Yokohama Municipal Citizen’s
Hospital in July 2002 because
Salmonella enterica serovar Paratyphi
A was detected in her urine. She had
no subjective symptoms such as pain
on urination or urinary urgency, and
her temperature was normal. She had
never had paratyphoid fever, and she
had not traveled abroad. No other per-
son in the community had paraty-
phoid. Before being admitted to the
hospital, she had experienced frequent
episodes of urinary tract infection and
had been empirically treated each
time with oral antimicrobial drugs,
including ciprofloxacin. She had been
given a dose of 600 mg/day for 7
days, 25 times in the last 4 years.
The patient did not display any
abnormal findings on physical exami-
nation. S. Paratyphi A was not detect-
ed in the urine but was confirmed in
the stool; therefore, the previous
report of bacteriuria could have been
due to contamination of a urine sam-
ple with feces. An ultrasound showed
a polyp and multiple stones in her
gallbladder. A carrier state was sus-
pected. Bile was obtained by duode-
nal aspiration and was positive for S.
Paratyphi A. The patient was consid-
ered to be an asymptomatic cholecys-
tic carrier of S. Paratyphi A.
On disk diffusion susceptibility
testing, the isolate was resistant to
nalidixic acid (NA) and to ofloxacin.
The MIC of ofloxacin was as high as
256 µg/mL, and the MIC of
ciprofloxacin was128 µg/mL (Table).
An open cholecystectomy was per-
formed for treatment of the polyp, the
stones, and the highly quinolone-
resistant bacteria. Aroutine periopera-
tive intravenous antimicrobial agent,
cefmetazole, was administered as sur-
gical prophylaxis. The polyp was
malignant, and the operation was
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curative. The patient resumed normal
activities, and had no further fecal
excretion of S. Paratyphi A.
Polymerase chain reaction (PCR)
amplification and DNA sequencing
were conducted to detect mutations
responsible for the fluoroquinolone
resistance. Nucleotide sequences of
gyrA,  gyrB,  parC, and parE genes
were investigated. The primers used
for PCR amplification and DNA
sequencing have been previously
described (6,7). An ABI Prism dye
terminator cycle sequencing kit
(Perkin-Elmer, Applied Biosystems,
Foster City, CA) and an automated
sequencer (311A; Perkin-Elmer,
Applied Biosystems) were used. The
isolated strain possessed triple point
mutations. The first 2 mutations were
in the gyrA gene, which encodes DNA
gyrase, at codon 83 (TCC to TTC),
which substitutes phenylalanine for
serine, and at codon 87 (GAC to
AAC), which substitutes asparagine
for aspartic acid. The third mutation
was in the parC gene, which encodes
DNA topoisomerase IV, at codon 84
(GAA to AAA), which substitutes
lysine for glutamic acid. No mutations
were found in gyrB and par E.
S. Typhi and Paratyphi A with
decreased susceptibility to fluoro-
quinolones emerged on the Indian
subcontinent, Southeast Asia, and
Central Asia in the mid-1990s (2–5).
On disk diffusion testing, these strains
were NA-resistant, and susceptible to
ofloxacin or ciprofloxacin; however,
the MICs of ciprofloxacin increased
to 0.25–4 µg/mL, 10- to 100-fold
higher than the usual NA–susceptible
strains (5,8,9). NA-resistant strains of
S. Typhi have 1 point mutation at the
target site of quinolones, DNAgyrase,
in the quinolone resistance–determin-
ing region of gyrA, either at codon 83
or codon 87 (2,3). Several epidemics
of typhoid and paratyphoid fever
caused by NA-resistant strains with
clinical failure of quinolone treatment
have been reported (4,5).
An experimental attempt had been
previously made to induce the pro-
duction of strains with high-level flu-
oroquinolone resistance by culturing
strains of S. Typhi and Paratyphi A in
ciprofloxacin-supplemented medium
(7). One of these in vitro–induced,
high-level resistant strains of S.
Paratyphi A had triple mutations in
the gyrA gene at codons 83 and 87 and
in the parC gene at codon 84, which
are the same triple mutations as those
seen in the current in vivo case.
Full fluoroquinolone resistance
has already emerged in the communi-
ty in nontyphoid Salmonella species.
In a clinical isolate of S. enterica
serovar Typhimurium, the MIC of
ciprofloxacin was 32 µg/mL, and
mutations in both gyrA and gyrB were
noted (10). 
Our findings strongly suggest that
high-level quinolone resistance was
induced through the long-term carrier
state of S. Paratyphi A under selective
pressure of frequent quinolone admin-
istration. The resistance is associated
with the 2 mutation sites in gyrA and 1
site in parC, and multiple point muta-
tions are likely related to the acquisi-
tion of full resistance. Physicians
should be aware of the emergence of
S. Typhi and Paratyphi A, as well as
nontyphoid Salmonella species, which
are highly quinolone-resistant.
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Pygmy Populations
Seronegative for
Marburg Virus
To the Editor: A serosurvey was
conducted in Durba, a mining village
near Watsa, northeastern Democratic
Republic of Congo, the epicenter of
Marburg hemorrhagic fever (MHF)
outbreaks in 1994 and 1998–2000
(1–3). In this survey, Bausch et al.
found a prevalence of anti-Marburg
immunoglobulin (Ig) G of 0.35% (2
of 565) in the nonmining population,
but a prevalence of 3.75% (13 of 347)
in miners. Mine work was an inde-
pendent risk factor for seropositivity
for anti-Marburg IgG (1). Given that
widespread secondary transmission
could not be documented in the
seropositive miners, primary trans-
mission from the unknown reservoir
likely occurred in the mines where
rodent, shrew, bat, and other fauna
were abundant. No evidence of
Marburg virus (MBGV) infection was
found in samples from small mam-
mals, amphibians, and arthropods col-
lected in and around Gorumbwa mine
(R. Swanepoel, pers. comm.); the ori-
gin of the MHF outbreak remained
unknown.
We hypothesized that the MBGV
reservoir’s habitat might not be limit-
ed to gold mines around Durba, but
may exist in caves or forests in the
wider Watsa area. As hunter-gather-
ers, pygmies enter caves for shelter
and are in frequent contact with wild
animals and body fluids of butchered
game. Earlier studies found that pyg-
mies were seropositive for filoviruses
significantly more often than subsis-
tence farmers (for filoviruses [4,5],
for Ebola but not Marburg [6]). We
conducted a seroprevalence study to
verify whether pygmies living in the
Watsa area constitute another popula-
tion at risk for primary transmission
of MBGV.
The Watsa area’s population
(≈180,000) includes 4,000 pygmies
living predominantly in its southern
parts (1). The pygmies live semino-
madically in the forest, occasionally
leaving to exchange goods with the
sedentary Bantu population.
We invited the pygmy population
to meet with our study representatives
at sites 50–90 km from Durba. Three
hundred persons volunteered during a
5-day period. After informed verbal
consent was obtained, the study par-
ticipants were interviewed, and a
blood sample was taken from each
volunteer. For operational reasons, we
excluded children <10 years old.
According to local customs, men
received small quantities of salt and
soap and women received an item of
second-hand clothing as an apprecia-
tion for their efforts. Ethical clearance
was obtained by the ethics committee
of the Institute of Tropical Medicine
in Antwerp and the representative of
the Ministry of Health in Watsa.
The study questionnaire was simi-
lar to one used in the Durba 1999 sur-
vey; we did not maintain a recall peri-
od of 1 year for exposures related to
medical treatment, as this did not
appear to be a meaningful time span
for the pygmies. Procedures for col-
lecting and handling blood samples
were similar to the Durba survey, and
the same laboratory tests were
applied. Serum samples were consid-
ered positive only if they were posi-
tive for Marburg IgG in both enzyme-
linked immunosorbent assay and indi-
rect immunofluorescence assay (IFA)
(1).
The study participants originated
from 39 different settlements. Their
median age was 30 years (range
10–75; q1 20, q3 40); half of them
were males. Most study participants
reported activities (hunting 60%,
entering caves 98%) and contacts
with wild animals (rodents 79%, bats
78%, monkeys or apes 99%) thought
to be risk factors for the primary
transmission of filoviruses. Whenever
noticeable differences existed
between the sexes, men tended to be
exposed more frequently than women,
often significantly so. Pygmies were
significantly more exposed to wild
animals than the nonmining general
population; the difference was partic-
ularly large concerning contact with
bats (Table). From one fourth to one
third of study participants reported a
direct or potential contact with some-
one with a febrile hemorrhagic syn-
drome. Women were more frequently
exposed to these risk factors for sec-
ondary transmission in the household
or community than men, sometimes
significantly so; pygmies were less
exposed to these risk factors than the
nonmining general population
(Table). Almost all study participants
had been exposed at least once in their